Pharmaceutical and MedTech organizations are continuing to advance their access to healthcare approaches. There is increased commitment to expanding access to medicines and diagnostics through corporate strategies, innovation through new models of care in emerging markets, and a greater focus on R&D for low- and middle-income country needs. There is also greater industry transparency, such the Access to Medicine Index which analyses how pharmaceutical companies are addressing access to medicine in 106 low- and middle-income countries.

There remain major gaps in access to health products and services across many countries, and much still to be done. However, increasingly there are committed pharma and medtech organisations striving to address this gap through their business, access and sustainability strategies.